Sustained Immunogenic and Clinical Effects of Low-Dose Interleukin-2 Therapy with an Intermittent Maintenance Method for Refractory Chronic Graft-Versus-Host Disease: Results of Phase1/2a LDIL2-01 Study

被引：0
|
作者：
Meguri, Yusuke [1 ]
Ohashi, Kazuteru [2 ]
Inamoto, Yoshihiro [3 ]
Iyama, Satoshi [4 ]
Ohwada, Chikako [5 ]
Murata, Makoto [6 ]
Satake, Atsushi [7 ]
Mori, Yasuo [8 ]
Nakase, Koichi [9 ]
Yoshida, Chikamasa [10 ]
Doki, Noriko [2 ]
Najima, Yuho [2 ]
Nishida, Tetsuya [6 ]
Maeda, Yoshinobu [1 ]
Matsuoka, Ken-ichi [1 ]
机构：
[1] Okayama Univ Hosp, Dept Hematol & Oncol, Okayama, Japan
[2] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Hematol Div, Tokyo, Japan
[3] Natl Canc Ctr, Dept Hematopoiet Stem Cell Transplantat, Tokyo, Japan
[4] Sapporo Med Univ Hosp, Dept Hematol, Sapporo, Hokkaido, Japan
[5] Chiba Univ Hosp, Dept Hematol, Chiba, Japan
[6] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Aichi, Japan
[7] Kansai Med Univ, Dept Internal Med 1, Osaka, Japan
[8] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka, Japan
[9] Ehime Prefectural Cent Hosp, Div Hematol, Matsuyama, Ehime, Japan
[10] Natl Hosp Org Minami Okayama Med Ctr, Div Hematol, Okayama, Japan
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2020年 / 26卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
256
引用
收藏
页码：S175 / S175
页数：1
相关论文
共 50 条
  • [41] Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study
    Barde, Francois
    Lorenzon, Roberta
    Vicaut, Eric
    Riviere, Sebastien
    Cacoub, Patrice
    Cacciatore, Carlotta
    Rosenzwajg, Michelle
    Daguenel-Nguyen, Anne
    Fain, Olivier
    Klatzmann, David
    Mekinian, Arsene
    RMD OPEN, 2024, 10 (02):
  • [42] Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
    Im, Annie
    Wolff, Daniel
    Cutler, Corey
    Zeiser, Robert
    Shah, Nirav N.
    Tan, Ming Tony
    Sanz, Jaime
    Ali, Haris
    Milone, Giuseppe
    LaW, Arjun D.
    Russo, Domenico
    Wagner, Eva-Maria
    Ivanova, Olga
    Hou, Kevin
    Bleam, Maureen
    Morariu-Zamfir, Rodica
    Pavletic, Steven Z.
    BLOOD, 2022, 140 : 1870 - 1871
  • [43] Updated Results of a Phase 1b/2 Study of Ibrutinib in Chronic Graft Versus Host Disease After Failure of Prior Therapy
    Waller, Edmund K.
    Miklos, David
    Cutler, Corey S.
    Arora, Mukta
    Jagasia, Madan
    Pusic, Iskra
    Flowers, Mary E.
    Logan, Aaron C.
    Nakamura, Ryotaro
    Dubovsky, Jason
    Chang, Stephen
    Clow, Fong
    Lal, Indu D.
    Styles, Lori
    Jaglowski, Samantha
    BONE MARROW TRANSPLANTATION, 2018, 53 : 71 - 73
  • [44] Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study
    Waller, Edmund K.
    Miklos, David
    Cutler, Corey
    Arora, Mukta
    Jagasia, Madan H.
    Pusic, Iskra
    Flowers, Mary E. D.
    Logan, Aaron C.
    Nakamura, Ryotaro
    Chang, Stephen
    Clow, Fong
    Lal, Indu D.
    Styles, Lori
    Jaglowski, Samantha
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (10) : 2002 - 2007
  • [45] Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial
    Garcia, Jorge A.
    Mekhail, Tarek
    Elson, Paul
    Triozzi, Pierre
    Nemec, Cheryl
    Dreicer, Robert
    Bukowski, Ronald M.
    Rini, Brian I.
    BJU INTERNATIONAL, 2011, 107 (04) : 562 - 570
  • [46] Low dose interleukin 2 for chronic graft-versus- host disease: a pilot study of The Francophon Society for Marrow Transplantation and Cellular Therapy (SFGM-TC)
    Berceanu, A.
    Bouaziz, J. D.
    Larosa, F.
    Daguindau, E.
    de Masson, A.
    Lioure, B.
    Rohrlich, P. S.
    Magro, L.
    de Latour, R. Peffault
    Deconinck, E.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S166 - S166
  • [47] KD025-208: A Phase 2a Study of 025 for Patients with Chronic Graft Versus Host Disease (cGVHD) - Pharmacodynamics and Updated Results
    Jagasia, Madan
    Salhotra, Amandeep
    Bachier, Carlos R.
    Essell, James
    Weisdorf, Daniel J.
    Zoghi, Behyar
    Green, Laurie S.
    Schueller, Olivier
    Zanin-Zhorov, Alexandra
    Weiss, Jonathan M.
    Eiznhamer, David
    Aggarwal, Sanjay K.
    Blazar, Bruce R.
    Lee, Stephanie J.
    BLOOD, 2018, 132
  • [48] JAK/Rock Inhibitor TQ05105 for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease: Preliminary Analysis Results of a Phase 1b/2 Study
    Zhao, Yanmin
    Tu, Lifan
    Ye, Yishan
    Luo, Yi
    Shi, Jimin
    Yu, Jian
    Yu, Yi
    Meng, Fankai
    Wang, Tao
    Huang, He
    BLOOD, 2022, 140 : 10505 - 10506
  • [49] IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A MULTICENTER OPEN-LABEL PHASE 2 STUDY
    Pusic, I.
    Miklos, D.
    Cutler, C.
    Arora, M.
    Waller, E.
    Jagasia, M.
    Flowers, M.
    Logan, A.
    Nakamura, R.
    Blazar, B.
    Li, Y.
    Lal, I.
    Dubovsky, J.
    James, D.
    Styles, L.
    Jaglowski, S.
    HAEMATOLOGICA, 2017, 102 : 186 - 186
  • [50] A phase 1/2 dose-finding, safety, and efficacy study of ibrutinib in paediatric patients with chronic graft versus host disease
    Locatelli, Franco
    Shaw, Peter
    Luan, Ying
    Sukbuntherng, Juthamas
    Wahlstrom, Justin
    Styles, Lori
    Carpenter, Paul
    BONE MARROW TRANSPLANTATION, 2019, 54 : 545 - 546
12345